Better, Sustainable & Digital transformation of health systems

through personalized precision medicine

Stephan Schaller

Founder & CEO esqlabs GmbH, Germany SME

~5.5yrs

~2.2yrs

Past experience in EU-funded projects

EU proposal coordinators and external evaluators

Contribute to three main pillars of

the EU Horizon 2020 programs

FP7 Health: Systems Biology of Ageing

H2020: Health, Demographics change & Wellbeing

H2020: e-Infrastructure (life Science)

H2020: Innovative Medicine Initiative (TransQST: Translational Quantitative Systems Toxicology)

FP7 Coordination Action: (GP-TCM)

2010 2012 2014 2016

FP7 Health: Adaptive clinical trial (Proposal Stage 1)

2018

H2020: Innovative Medicine Initiative (BD4BO: Big data for better outcomes pancreatic cancer)

~5 yrs (preclinical scientist: bioinformatics & systems biology)

REACTION: Remote (IoT) Diabetes Management Technologies GlucoSYS: Personalized Management of Blood Glucose in the ICU OSMOSES: Technology dev. to make ML in Health/Pharma more efficient

Kah-Tong, SEOW Ph.D. (Molecular neurobiology) M.Sc. (Knowledge Engineering) Esqlabs since Apr 2019 Bioinformatics & Lead Cloud Developer

Past & Present Esqlabs GmbH Funding Projects

Digital transformation of healthcare ~6 yrs

• Disease Physiology

– Organ patho-physiology

– Disease mechanisms

All purpose in silico precision medicine disease-base platform

• Compound Properties

– MW, lipophilicity,…

– ka, kd, metabolization, …

• Physiology-specific

– Age, Weight, Height

– Gender, Species, Ethnicity

• Protein Expression/Omics

Blausen.com staff. "Blausen gallery 2014". Wikiversity Journal of Medicine

Adapted from: Hirsch IB. Insulin analogues.

Nature.com

Who We Are

Pharma R&D

We support Go/NoGo decisions by integration of R&D data to build knowledge and improve understanding of drug & disease.

Specialty Patient Care

We leverage R&D knowledge to optimize dosing for efficient and safe personalized treatments for an improved quality of care.

Software and Tool Development We build and customize OPEN-SOURCE tools and software for

integrated model-based drug discovery, development and dosing (MID4)

“esqLABS is a private SME

We develop and utilizes computational tools to predict patient-level treatment outcomes in pharma research and care to support our customers decision making process.”

BETTER HEALTH AND CARE

Innovative health and care industry:

SC1-BHC-11-2020 Chemical safety assessment – Non-animal testing Advancing the safety assessment of chemicals without the use of animal testing

• Unlocking the power of (quantitative!) virtual populations:

– Optimal clinical trial design and prediction of trial outcome

• Assess/optimize cohort selection, titration rules, measurement intervals and clinical endpoints for proof of efficacy/superiority

– Optimize your medical device strategy

• Assess effect of delivery device settings (i.e. insulin pumps) on product & treatment efficacy

Target

Identification &

Validation

Lead

Identification&

Optimization

Preclinical

Development

Clinical

Phase I

Clinical

Phase II

Clinical

Phase III

Clinical trial smulation & optimization

with virtual populations based on in-

vitro data

DIGITAL TRANSFORMATION

Disrupting health and care industry:

SC1-DTH-06-2020: Computer solutions for testing medicines Accelerating the uptake of computer simulations for testing medicines and medical devices

• Genomics • (treatment) target and co-factor expression

• Metabolomics (& metabolic fluxes) • Disease Progression

• changes in physiology and disease mechanisms

• Pharmacological data • In-vitro & pharmacokinetics and -dynamics

Leverage Patient-level data and ML to generate a “digital twin” / “in-silico patient”

Contact details

• Stephan Schaller

• Esqlabs GmbH

• esqLABS GmbH | Hambierich 34 | 26683 Saterland | Germany

• Phone: +49 151 / 58559070

• E-mail: partnering@esqlabs.com

Appendix

BETTER HEALTH AND CARE

Personalised medicine:

SC1-HCO-03-2020: Support for low performing countries Bridging the divide in health research and innovation – boosting return on investment

BETTER HEALTH AND CARE

Personalised medicine:

SC1-HCO-17-2020: Human microbiome – Coordinating research Coordinating and supporting research on the human microbiome in Europe and beyond

Figure 4: Prediction of incretin response to oral administration of glucose solution: Panel A: Simulated (lines) and observed (symbols ±SD) concentrations of GLP-1 after administration of 50 g (red) and 100 g (blue) glucose solution. Data from [7]. Panel B: Simulated (lines) and observed (symbols ±SD) concentrations of GIP after administration of 50 g (red) and 100 g (blue) glucose solution. Data from [7].

BETTER HEALTH AND CARE

Contribution to the Call on Digital transformation:

SC1-HCC-10-2020: Health Research and Innovation Cloud data portal Towards a Health research and innovation Cloud: Capitalising on data sharing initiatives in health research

esqlabs precision medicine module

TRANSFORMING EUROPEAN INDUSTRY

H2020-NMBP-TR-IND-2020

NMBP-21-2020: Custom-made biological scaffolds for specific tissue regeneration and repair

A single disease platform to test and validate the custom-made biological scaffolds using a multiscale, from single cell to organs to whole body precision medicine simulation platform.

• Physiology-specific

– Age, Weight, Height

– Gender, Species, Ethnicity

• Protein Expression

• Compound Properties

– MW, lipophilicity,…

– ka, kd, metabolization, …

• Disease Physiology

– Organ patho-physiology

– Disease mechaisms

Blausen.com staff. "Blausen

gallery 2014".

Wikiversity Journal of Medicine

Adapted from: Hirsch IB. Insulin analogues.

Nature.c

om

Nature.c

om